Cancer Organoids Multiplexed Screening in Microfluidic Textile chips
The development of precision and personalized medicine, notably in cancer, leads to an explosion in the cost of research, clinical trials, diagnosis and treatment. It calls for a change of paradigm in cell-based personalized model...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
3DPD
PhD position in commercial environment cancer immunotherapy...
135K€
Cerrado
MTOAC
Multi compartmental Tumor on a Chip
185K€
Cerrado
RTI2018-094494-B-C22
DISEÑO DE HERRAMIENTAS DE MICROSCOPIA TRIDIMENSIONAL Y PROCE...
129K€
Cerrado
CellPrintArray
CellPrintArray on demand nano scale printing of live cells...
150K€
Cerrado
POC-TDM
Development of a point-of-care microfluidic device for Thera...
158K€
Cerrado
EQC2021-007516-P
MIcroscopia de CRibado de Alto Contenido para el estudio de...
654K€
Cerrado
Información proyecto COMMiT
Duración del proyecto: 31 meses
Fecha Inicio: 2020-03-17
Fecha Fin: 2022-10-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The development of precision and personalized medicine, notably in cancer, leads to an explosion in the cost of research, clinical trials, diagnosis and treatment. It calls for a change of paradigm in cell-based personalized models, allowing-high throughput screening of large panels of drugs at low cost and on minute samples. We invented in ERCadg CellO a new technology Free-Flow Textile Chips (FFTC) proving a solution to the above problem. It allows the production of high-resolution complex microfluidic devices at very low cost using the power of the textile industry. Using this technology we developed an automated platform able to generate, from a single micro-biopsy, a large number of 3D tumor cell spheroids encapsulated within individual nanoliter droplets, and to screen them against tens of drug combinations. This platform will reduce the time, sample size, cost of screening and drugs consumption per assay by factors ranging from 10 to 1000. This will in turn replace animal testing, and allow low-cost high-content drug screening and affordable precision medicine. This new platform will be tested versus conventional techniques in a real world context, and steps towards industrialization will be taken. We shall first target the market of research laboratories and drug development in the pharmaceutical industry, but also prepare clinical applications to the personalization of anticancer treatments. Beyond this, FFTC represents a major breakthrough in microfluidics, a technological field that is currently revolutionizing biology and medicine. Currently its democratization and societal impact are limited by fabrication costs. FFTC will overcome this barrier. COMMiT will thus pave the route to a wide range of other applications, such as point-of-care devices or organs-on-chip to replace animal testing.